Apoptosis in mammalian eye development: Lens morphogenesis, vascular regression and immune privilege

被引:65
作者
Lang, RA [1 ]
机构
[1] NYU MED CTR, DEPT PATHOL, DEV GENET PROGRAM, SKIRBALL INST BIOMOL MED, NEW YORK, NY 10016 USA
基金
美国国家卫生研究院;
关键词
programmed cell death; apoptosis; development; eye;
D O I
10.1038/sj.cdd.4400211
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Formation of the mammalian eye requires a complex series of tissue interactions that result in an organ of exquisite sensory capability, The early steps in eye development involve extensive cell death associated with morphogenesis, Later, suppression of programmed cell death is essential for tissue differentiation and in the adult, the immune privileged status of the eye is maintained in part through factors that induce inflammatory cell apoptosis, Experimental evidence suggests that suppression of apoptosis in cells of the lens lineage by fibroblast growth factors is one component of their action during lens morphogenesis, Fibroblast growth factors are also required for normal lens fiber-cell differentiation, This includes a degenerative step for organelles that is presumably an adaptation for the clearance of light scattering elements from the optic axis. The process of organelle degeneration may be related to apoptosis in a few of its features. Actively-induced apoptosis becomes important for eye development as the temporary ocular vasculatures regress. This too, is presumably an adaptation far the disposal of cells that would disturb the passage of light to the retina, Ocular macrophages appear to be essential for the induction of apoptosis in the endothelial cells comprising the ocular vasculatures. In the adult, inflammatory cells entering the eye are exposed to the pro-apoptotic agents transforming growth factor-beta(2) and Fas ligand, The expression of these molecules in the eye, and their action in killing inflammatory cells, has evolved as a means of preventing inflammation and subsequent loss of vision, Thus, the eye offers a unique and versatile system for studying the role of programmed cell death in lens development, vascular regression and immune privilege.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 77 条
  • [21] Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated
    Diebold, RJ
    Eis, MJ
    Yin, MY
    Ormsby, I
    Boivin, GP
    Darrow, BJ
    Saffitz, JE
    Doetschman, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (26) : 12215 - 12219
  • [22] DISRUPTION OF EPITHELIAL CELL-MATRIX INTERACTIONS INDUCES APOPTOSIS
    FRISCH, SM
    FRANCIS, H
    [J]. JOURNAL OF CELL BIOLOGY, 1994, 124 (04) : 619 - 626
  • [23] IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION
    GAVRIELI, Y
    SHERMAN, Y
    BENSASSON, SA
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 493 - 501
  • [24] CELL DEATHS IN NORMAL VERTEBRATE ONTOGENY
    GLUCKSMANN, A
    [J]. BIOLOGICAL REVIEWS OF THE CAMBRIDGE PHILOSOPHICAL SOCIETY, 1951, 26 (01): : 59 - 86
  • [25] THE RETINOBLASTOMA GENE-PRODUCT REGULATES PROGRESSION THROUGH THE G1 PHASE OF THE CELL-CYCLE
    GOODRICH, DW
    WANG, NP
    QIAN, YW
    LEE, EYHP
    LEE, WH
    [J]. CELL, 1991, 67 (02) : 293 - 302
  • [26] EMBRYONIC LENS INDUCTION - SHEDDING LIGHT ON VERTEBRATE TISSUE DETERMINATION
    GRAINGER, RM
    [J]. TRENDS IN GENETICS, 1992, 8 (10) : 349 - 355
  • [27] GRANSTEIN RD, 1990, J IMMUNOL, V144, P3021
  • [28] THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR
    GRELL, M
    DOUNI, E
    WAJANT, H
    LOHDEN, M
    CLAUSS, M
    MAXEINER, B
    GEORGOPOULOS, S
    LESSLAUER, W
    KOLLIAS, G
    PFIZENMAIER, K
    SCHEURICH, P
    [J]. CELL, 1995, 83 (05) : 793 - 802
  • [29] FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE
    GRIFFITH, TS
    BRUNNER, T
    FLETCHER, SM
    GREEN, DR
    FERGUSON, TA
    [J]. SCIENCE, 1995, 270 (5239) : 1189 - 1192
  • [30] Hansson M, 1996, J IMMUNOL, V156, P42